MARATTO

article · Vaccines

Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries

2021363 citationsOpen accessUniversité de Kinshasa (UNIKIN)

In plain language

This study surveyed over 10,000 individuals across nine Low- and Middle-Income Countries to understand COVID-19 vaccine acceptance. It found that acceptance rates rose significantly, from 76.4% to 88.8%, when vaccine effectiveness was perceived to be higher (90% versus 95%). Several countries, including Malaysia, Thailand, Bangladesh, and five African nations, showed lower acceptance odds compared to Brazil. Factors positively associated with vaccine acceptance included believing the vaccine protects oneself, good COVID-19 knowledge, worry about the virus, higher income, and younger age. Conversely, having a chronic disease or being female reduced acceptance odds. The main reasons for refusing vaccination were fear of side effects (41.2%) and a lack of confidence in the vaccine's effectiveness (15.1%).

Key takeaways

  • COVID-19 vaccine acceptance in Low- and Middle-Income Countries increased from 76.4% to 88.8% when perceived effectiveness rose from 90% to 95%.
  • Malaysia, Thailand, Bangladesh, and five African countries had lower vaccine acceptance odds compared to Brazil.
  • Perceiving the vaccine as important for personal protection, higher COVID-19 knowledge, worry about the virus, higher income, and younger age were associated with increased acceptance.
  • Chronic disease and female gender were associated with reduced odds of vaccine acceptance.
  • The primary reasons for vaccine refusal were fear of side effects and a lack of confidence in vaccine effectiveness.

Why it matters

Understanding the factors influencing COVID-19 vaccine acceptance and refusal in Low- and Middle-Income Countries is crucial for developing effective public health campaigns. This knowledge can help tailor strategies to address specific concerns, improve vaccine uptake, and ensure equitable protection against the pandemic globally.

Commercialisation angle

The abstract indicates that further research is needed to identify country-specific reasons for vaccine hesitancy to develop mitigation strategies. This work is foundational for public health policy and intervention design, aiming to improve vaccination coverage. It does not directly suggest a commercial product or service, but rather informs public health programmes and communication efforts.

AI-generated from the published abstract. Always read the original work before citing.

Abstract

Vaccination is fast becoming a key intervention against the ongoing COVID-19 pandemic. We conducted cross-sectional online surveys to investigate COVID-19 vaccine acceptance across nine Low- and Middle-Income Countries (LMICs; <i>N</i> = 10,183), assuming vaccine effectiveness at 90% and 95%. The prevalence of vaccine acceptance increased from 76.4% (90% effectiveness) to 88.8% (95% effectiveness). Considering a 90% effective vaccine, Malaysia, Thailand, Bangladesh, and five African countries (Democratic Republic of Congo, Benin, Uganda, Malawi, and Mali) had lower acceptance odds compared to Brazil. Individuals who perceived taking the vaccine as important to protect themselves had the highest acceptance odds (aOR 2.49) at 95% effectiveness.Vaccine acceptance was also positively associated with COVID-19 knowledge, worry/fear regarding COVID-19, higher income, younger age, and testing negative for COVID-19. However, chronic disease and female gender reduced the odds for vaccine acceptance. The main reasons underpinning vaccine refusal were fear of side effects (41.2%) and lack of confidence in vaccine effectiveness (15.1%). Further research is needed to identify country-specific reasons for vaccine hesitancy in order to develop mitigation strategies that would ensure high and equitable vaccination coverage across LMICs.

Research topics

  • Vaccine Coverage and Hesitancy
  • SARS-CoV-2 and COVID-19 Research
  • Misinformation and Its Impacts

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3390/vaccines9050515

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.